MINIMAL ADENOCARCINOMA IN PROSTATE NEEDLE BIOPSY TISSUE: IMMUNOHISTOCHEMICAL STUDY (original) (raw)
Related papers
Evaluation of a new tumor marker for localized prostate cancer
The Prostate, 1992
Adenocarcinoma associated antigen (ACAA) is a large molecular weight protein that is normally found in low semm levels. Recent data have revealed elevations in patients with adenocarcinomas, including prostate cancer. To evaluate the relationship of ACAA levels with prostate cancer, we measured the cytosol content in malignant and nonmalignant prostate tissue and compared these results to those of the standard markers, prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA). Enzyme solid phase immunoassay was used to quantitate PSA and ACAA levels, and the enzymatic method was used to measure PAP. Wedge resection from the right and left posterior lobes of 50 fresh radical retmpubic prostatectomy specimens were used for cytosol analysis. All foci of cancer within each prostate gland were carefully mapped by a single pathologist. When all malignant wedges (N = 74) were compared to all the benign wedges (N = 21), only the PSA levels showed significant elevation (p < 0.02). However, when benign and malignant tissue from the same prostate were available for comparison, both PSA (N = 17) and ACAA (N = 16) showed significant elevations in the cytosol of the malignant tissue (p < 0.002 and p < 0.03, respectively). Although not statistically significant, the cytosol PAP did show a consistent trend to be greater in malignant tissue. It appears that there is an association of increased cytosol ACAA and PSA with prostate cancer.
IP innovative publication pvt. ltd, 2019
Introduction: The spectrum of diseases affecting the prostate gland in men can be inflammatory, benign, premalignant lesions and malignancy. Major diagnostic challenge of surgical prostate biopsy interpretation is either due to a small focus of cancer or presence of various benign mimickers of malignancy which is labeled as suspicious foci. Aim of the study was to evaluate complete histopathological spectrum of lesions encountered on transrectal ultra sonography (TRUS) guided prostate needle biopsy and transurethral resection of prostate (TURP) chips and to use immunohistochemistry (IHC) markers like Alpha-methylacyl-Co enzyme A racemase (AMACR) and p63 as an adjunct in resolving the suspicious cases. Materials and Methods: We assessed total 60 cases of prostatic specimens received during December 2015 to November 2017. The received specimens were routinely processed and histopathological examination was carried out. IHC for AMACR and p63 was performed and results were analyzed using SPSS software. Results: Majority of cases were benign prostatic hyperplasia (BPH) (73.3%). Incidence of prostate cancer was low (16.6%). After IHC, out of the six (10%) histomorphologically suspicious cases, three cases were positive for only AMACR; two cases were positive for only p63 and one case showed positivity for both. Immunohistochemistry with AMACR and p63 proved to be highly sensitive markers for detecting malignancy but AMACR marker showed less specificity. Conclusion: Histomorphologically, benign lesions of prostate are more common than malignant ones. Combination of AMACR and p63 IHC enhances the diagnostic accuracy in suspicious cases by identifying premalignant lesions or malignancy and reduces misdiagnosis.
Journal of Science and Technology
ABSTRACT: The objective of this study was to evaluate the validity of prostate specific antigen (PSA), carcino embryonic antigen (CEA), human epidermal growth factor 2 (Her2), B cell 2 (BcL2), protein 53 (P53) and high molecular wight cytokeratin (HMW) tumor markers in the identification and differential diagnosis of prostate tumors. Biopsy samples were randomly taken from patients with prostate tumors. Tissue sections were prepared and stained for histopathology and immunohistochemistry. Out of the 100 patients with prostatic lesions, 25% had benign prostatic hyperplasia, 42% and 33% have a well differentiated and poorly differentiated adenocarcinoma, respectively. The results revealed a significant correlation between prostate cancer and tissue expression of CEA, P53 and HMW cytokeratin tumor markers. No significant relation was found between prostate cancer and tissues expression of Her2, PSA and Bcl2 tumor markers. A significant relation between tobacco usage and prostate cancer...
Pathology and bio markers of prostate cancer
Prostate Cancer and Prostatic Diseases, 1999
This session included ®ve presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new`molecular' markers, correlation between pre-and postoperative Gleason scores and a study dealing with transition zone PSA density. The abstracts and talks are summarized in the next few pages.
Markers for the development of early prostate cancer
The Journal of Pathology, 2003
Biochemical and genetic changes precede histologically identifiable changes accompanying cell transformation often by months or years. De-expression of the extracellular matrix adhesive glycoprotein tenascin and the cell-to-cell adherent protein E-cadherin have been suggested as markers of early neoplastic change in prostate epithelial cells. Previous studies have been inconclusive, probably due to epitope masking. This study examined 2378 biopsy cores from 289 prostates using a heat antigen retrieval protocol at low pH to improve the accuracy of detection. Tenascin and E-cadherin de-expression was correlated with purinergic receptor and telomerase-associated protein labelling, as well as prostatespecific antigen (PSA) levels and Gleason scores. E-cadherin was a poor marker, as it was expressed in all lesions except carcinomas of the highest Gleason score. Tenascin was maximally expressed in the extracellular matrix and acinar basement membrane in normal and prostatic intraepithelial neoplasia tissue. In prostate cancer tissue, tenascin expression did not correlate with Gleason score but was significantly de-expressed as purinergic receptor and telomerase-associated protein expression increased. Marked changes in tenascin, telomerase-associated protein, and purinergic receptor expression were apparent before any histological abnormalities were visible by haematoxylin and eosin (H&E) stain, making these potential markers for early and developing prostate cancer. Moreover, the potential increased accuracy of diagnosis of underlying prostate cancer using purinergic receptor translocation (PRT) assessment suggests that PSA levels may be more accurate than has generally been supposed when apparent false negatives arising from H&E-based diagnoses are correctly categorized.